Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diabetes

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    September 2019
  1. SANTULLI G
    In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years.
    Ann Intern Med. 2019;171:JC31.
    PubMed     Text format    


  2. EL KAWKGI OM, Montori VM
    In high-risk type 1 diabetes, insulin pumps with suspend-before-low technology reduced hypoglycemic events.
    Ann Intern Med. 2019;171:JC30.
    PubMed     Text format    


  3. LIPSCOMBE LL
    In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
    Ann Intern Med. 2019;171:JC29.
    PubMed     Text format    


  4. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
    Ann Intern Med. 2019;171:JC28.
    PubMed     Text format    


  5. LIPSCOMBE LL
    In patients >/= 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
    Ann Intern Med. 2019;171:JC27.
    PubMed     Text format    


    August 2019
  6. GOEL A
    In type 2 diabetes, a primary care-led weight management program increased weight loss and diabetes remission at 2 years.
    Ann Intern Med. 2019;171:JC17.
    PubMed     Text format    


  7. LIPSCOMBE LL
    In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
    Ann Intern Med. 2019;171:JC16.
    PubMed     Text format    


  8. PATEL T
    Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease.
    Ann Intern Med. 2019;171:JC15.
    PubMed     Text format    


  9. CHAMBERLAIN JJ, Doyle-Delgado K, Peterson L, Skolnik N, et al
    Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2019 Aug 13. pii: 2748278. doi: 10.7326/M19-1638.
    PubMed     Text format     Abstract available


    July 2019
  10. JACKSON GL, Smith VA, Edelman D, Hendrix CC, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:145.
    PubMed     Text format    


  11. KUMAR PD
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144.
    PubMed     Text format    


  12. GROTE J
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants.
    Ann Intern Med. 2019;171:144-145.
    PubMed     Text format    


  13. KE C, Shah BR, Stukel TA, Chan JCN, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78-79.
    PubMed     Text format    


  14. FINUCANE TE
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes.
    Ann Intern Med. 2019;171:78.
    PubMed     Text format    


    May 2019
  15. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - Cardiovascular Risk, Blood Pressure, and Cognition in a Patient With Diabetes.
    Ann Intern Med. 2019;170:CG1.
    PubMed     Text format    


  16. GOEL A
    Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes.
    Ann Intern Med. 2019;170:JC51.
    PubMed     Text format    


    April 2019
  17. LUDVIGSSON JF, Neovius M, Soderling J, Gudbjornsdottir S, et al
    Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731602. doi: 10.7326/M18-1974.
    PubMed     Text format     Abstract available


  18. APOLZAN JW, Venditti EM, Edelstein SL, Knowler WC, et al
    Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Ann Intern Med. 2019 Apr 23. pii: 2731601. doi: 10.7326/M18-1605.
    PubMed     Text format     Abstract available


  19. KANSAGARA D, Humphrey LL, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583-584.
    PubMed     Text format    


  20. GOOD CB, Kolb NR, Meyer M
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification.
    Ann Intern Med. 2019;170:583.
    PubMed     Text format    


  21. PUNTHAKEE Z
    In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year.
    Ann Intern Med. 2019;170:JC40.
    PubMed     Text format    


  22. DAVIDSON MB
    Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes.
    Ann Intern Med. 2019;170:JC39.
    PubMed     Text format    


  23. ARTERBURN D
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507-508.
    PubMed     Text format    


  24. KWON Y, Park S
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:507.
    PubMed     Text format    


  25. CARLSSON L, Carlsson B, Peltonen M
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2019;170:506-507.
    PubMed     Text format    


    January 2019
  26. KE C, Lau E, Shah BR, Stukel TA, et al
    Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes: A Population-Based Cohort Study.
    Ann Intern Med. 2019 Jan 15. pii: 2720956. doi: 10.7326/M18-1900.
    PubMed     Text format     Abstract available


    December 2018

  27. Correction: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018;169:899.
    PubMed     Text format    


  28. SANTULLI G
    In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
    Ann Intern Med. 2018;169:JC67.
    PubMed     Text format    


    November 2018
  29. JACKSON GL, Smith VA, Edelman D, Woolson SL, et al
    Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants: A Cohort Study.
    Ann Intern Med. 2018 Nov 20. pii: 2716077. doi: 10.7326/M17-1987.
    PubMed     Text format     Abstract available


  30. WHARAM JF, Lu CY, Zhang F, Callahan M, et al
    High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes.
    Ann Intern Med. 2018 Nov 20. pii: 2716078. doi: 10.7326/M17-3365.
    PubMed     Text format     Abstract available



  31. The Effect of High-Deductible Insurance Plans on Diabetes Care.
    Ann Intern Med. 2018 Nov 20. pii: 2716396. doi: 10.7326/P18-0018.
    PubMed     Text format    



  32. Comparing Diabetes Outcomes for Primary Care Provided by Physicians, Nurse Practitioners, and Physician Assistants.
    Ann Intern Med. 2018 Nov 20. pii: 2715823. doi: 10.7326/P18-0017.
    PubMed     Text format    


  33. TANNER M
    Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes.
    Ann Intern Med. 2018;169:JC59.
    PubMed     Text format    


    September 2018
  34. CENTOR RM, Barry MJ
    Web Exclusive. Annals On Call - Oral Pharmacologic Therapy in Type 2 Diabetes: Choosing Therapy Wisely.
    Ann Intern Med. 2018;169:OC1.
    PubMed     Text format    


  35. HUMPHREY LL, Kansagara D, Qaseem A
    World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee.
    Ann Intern Med. 2018 Sep 4. pii: 2698899. doi: 10.7326/M18-1148.
    PubMed     Text format    


  36. ROGLIC G, Norris SL
    Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the
    Ann Intern Med. 2018 Sep 4. pii: 2698900. doi: 10.7326/M18-1149.
    PubMed     Text format     Abstract available


  37. CENTOR RM, Montori VM
    Web Exclusive. Annals On Call - Glycemic Control in Type 2 Diabetes: How Low Should We Go?
    Ann Intern Med. 2018;169:OC1.
    PubMed     Text format    


    August 2018

  38. Prevention of Diabetes With Mediterranean Diets.
    Ann Intern Med. 2018;169:271-272.
    PubMed     Text format    


  39. O'BRIEN R, Johnson E, Haneuse S, Coleman KJ, et al
    Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.
    Ann Intern Med. 2018 Aug 7. pii: 2696493. doi: 10.7326/M17-2383.
    PubMed     Text format     Abstract available



  40. Outcomes of Bariatric Surgery in Patients With Diabetes.
    Ann Intern Med. 2018 Aug 7:1. doi: 10.7326/P18-0012.
    PubMed     Text format    


    July 2018
  41. EGAN AM, Montori VM
    Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis.
    Ann Intern Med. 2018;169:JC3.
    PubMed     Text format    


  42. EGAN AM, Montori VM
    Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
    Ann Intern Med. 2018;169:JC2.
    PubMed     Text format    


  43. MADENIDOU AV, Paschos P, Karagiannis T, Katsoula A, et al
    Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Ann Intern Med. 2018 Jul 10. pii: 2687651. doi: 10.7326/M18-0443.
    PubMed     Text format     Abstract available


    June 2018
  44. HIRSCH IB, Skyler JS
    Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686099. doi: 10.7326/M18-1473.
    PubMed     Text format    


  45. SCHROEDER EB, Karter AJ
    Brief Commentary: Glycemic Targets for Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686097. doi: 10.7326/M18-1471.
    PubMed     Text format    


  46. MILES DRB
    Brief Commentary: Social Determinants of Health and Treatment Targets for Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686098. doi: 10.7326/M18-1472.
    PubMed     Text format    


  47. BURKE BV, Hedin S
    Brief Commentary: Laboratory Accuracy of Hemoglobin A1c Ranges and Treatment Targets for Patients With Type 2 Diabetes.
    Ann Intern Med. 2018 Jun 26. pii: 2686219. doi: 10.7326/M18-1482.
    PubMed     Text format    


  48. NARAYAN KMV, Jagannathan R
    Two in One: Diagnosing Type 2 Diabetes With Single-Sample Testing.
    Ann Intern Med. 2018 Jun 19. pii: 2685289. doi: 10.7326/M18-1477.
    PubMed     Text format    


  49. SELVIN E, Wang D, Lee AK, Coresh J, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900-901.
    PubMed     Text format    


  50. PETERSEN MP, Cefalu WT
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults.
    Ann Intern Med. 2018;168:900.
    PubMed     Text format    


  51. SELVIN E, Wang D, Matsushita K, Grams ME, et al
    Prognostic Implications of Single-Sample Confirmatory Testing for Undiagnosed Diabetes: A Prospective Cohort Study.
    Ann Intern Med. 2018 Jun 19. pii: 2684927. doi: 10.7326/M18-0091.
    PubMed     Text format     Abstract available


    May 2018
  52. MOIST L
    In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Ann Intern Med. 2018;168:JC52.
    PubMed     Text format    


    April 2018
  53. BEKIARI E, Karagiannis T, Tsapas A
    In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
    Ann Intern Med. 2018;168:JC46.
    PubMed     Text format    


  54. VIGERSKY RA
    Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections.
    Ann Intern Med. 2018;168:528.
    PubMed     Text format    


  55. BECK RW, Riddlesworth TD
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:526-527.
    PubMed     Text format    


  56. HAAK T
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:525-526.
    PubMed     Text format    


  57. CHAMBERLAIN JJ, Johnson EL, Leal S, Rhinehart AS, et al
    Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Ann Intern Med. 2018 Apr 3. pii: 2677350. doi: 10.7326/M18-0222.
    PubMed     Text format     Abstract available


    March 2018
  58. GOEL A
    Intensive weight management in primary care improved weight loss and remission of type 2 diabetes.
    Ann Intern Med. 2018;168:JC30.
    PubMed     Text format    



  59. Hemoglobin A1c Targets for Nonpregnant Adults With Type 2 Diabetes Mellitus.
    Ann Intern Med. 2018 Mar 6. pii: 2674123. doi: 10.7326/P18-0003.
    PubMed     Text format    


  60. QASEEM A, Wilt TJ, Kansagara D, Horwitch C, et al
    Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.
    Ann Intern Med. 2018 Mar 6. pii: 2674121. doi: 10.7326/M17-0939.
    PubMed     Text format     Abstract available


    January 2018
  61. GENERE N, Montori VM
    Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
    Ann Intern Med. 2018;168:JC8.
    PubMed     Text format    


    December 2017
  62. LIPSCOMBE LL
    Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
    Ann Intern Med. 2017;167:JC67.
    PubMed     Text format    


  63. LIPSCOMBE LL
    Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;167:JC66.
    PubMed     Text format    



  64. Cost-Effectiveness of Individualized Management of Diabetes Among U.S. Adults.
    Ann Intern Med. 2017 Dec 12. pii: 2665905. doi: 10.7326/P17-9050.
    PubMed     Text format    


  65. LAITEERAPONG N, Cooper JM, Skandari MR, Clarke PM, et al
    Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Ann Intern Med. 2017 Dec 12. pii: 2665902. doi: 10.7326/M17-0537.
    PubMed     Text format     Abstract available


    October 2017
  66. SELVIN E, Wang D, Lee AK, Bergenstal RM, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1272.
    PubMed     Text format     Abstract available


  67. CONLIN PR, Colburn J, Aron D, Pries RM, et al
    Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1362.
    PubMed     Text format     Abstract available


  68. PETERS AL
    Rethinking Rates of Undiagnosed Diabetes: The Value of a Confirmatory Test.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-2576.
    PubMed     Text format    


  69. DASGUPTA I, Singh AK
    Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death.
    Ann Intern Med. 2017;167:JC47.
    PubMed     Text format    


  70. MURFF HJ
    Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non-insulin-treated type 2 diabetes.
    Ann Intern Med. 2017;167:JC46.
    PubMed     Text format    


    September 2017
  71. CHAMBERLAIN JJ, Kalyani RR, Leal S, Rhinehart AS, et al
    Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Sep 12. doi: 10.7326/M17-1259.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: